Spike (B.1.351/ Beta Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)
Product Code
AMS.78160-2
$0.00
Order Support
-
Email: [email protected]
Order Support
- Email: [email protected]
Order Support
- Email: [email protected]
Order Support
-
T: +1 (800) 987 0985 (toll free)
-
Email: [email protected]
Order Support
-
Email: [email protected]
Shipping Information
-
Delivery charges will be calculated during checkout
Product Updates
-
Keep up to date with product offers, resources and news
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication/ the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes/ endothelial cells/ and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.
A variant called B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This South African variant/ also known as 501Y.V2/ has many mutations that may lead to higher transmissibility and infectivity. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter/ therefore/ the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (B.1.351) variant in a Biosafety Level 2 facility.
A variant called B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This South African variant/ also known as 501Y.V2/ has many mutations that may lead to higher transmissibility and infectivity. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter/ therefore/ the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (B.1.351) variant in a Biosafety Level 2 facility.
SKU | AMS.78160-2 |
---|---|
Size | 500 ul x 2 |
Species | SARS-CoV-2 |
Application | 1. Study the mechanism of viral transduction of SARS-CoV-2 (B.1.351 variant) 2. Screening for neutralizing antibodies for SARS-CoV-2 Spike (B.1.351 variant) and ACE2. |
Gene synonyms | coronavirus, covid, covid-19, covid19, 501Y.V2, sars cov 2, sarscov2, South Africa variant, South Africa lenti, South Africa mutation, South Africa lentivirus, pseudovirus, pseudovirion, eGFP reporter, B1135, 78160-1, 78160-2 |
Storage | Lentiviruses are shipped with dry ice. For long term storage/ it is recommended to store the virus at -80C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle. |
Shipping Temp | -80C (dry ice) |
Supplier Name | BPS |